MHRA Updates Guidance on Serious Adverse Events Reporting

The Medicines and Healthcare products Regulatory Agency (MHRA) issued an important update to its Clinical Investigation Guidance, with a focus on the reporting of Serious Adverse Events (SAEs). The updated guidance provides essential clarification on how SAEs should be handled during clinical investigations of medical devices. 

MHRA Clarifies Serious Adverse Event Reporting Requirements and Streamlines Process

Previously, there may have been some uncertainty about whether all serious adverse events, regardless of their initial assessment, needed to be reported. With the latest update, the MHRA has confirmed that all SAEs must be reported to ensure proper safety monitoring. This includes events that are initially considered unrelated to the device or procedure involved. By requiring all serious events to be reported, the MHRA aims to ensure that incidents are documented in a timely manner, allowing them to assess whether further investigation or action is needed. 

In addition to this clarification, the updated guidance now provides direct links to the MORE portal. This feature is designed to simplify the process of submitting reports and ensures that clinical investigators have quick access to the correct portal for reporting serious adverse events. This enhancement streamlines the reporting process, making it easier for investigators to comply with regulatory requirements and facilitating better oversight of clinical investigations. 

The MHRA’s decision to make these updates reflects a broader commitment to patient safety and regulatory transparency. By ensuring that all serious events are captured, the MHRA can more effectively monitor potential risks and take appropriate action when necessary. 

For further details, you can access the full Clinical Investigations Guidance here or on GOV.UK. 

This update underscores the MHRA’s ongoing efforts to maintain the highest standards of safety and regulatory compliance within the medical device sector, supporting the industry in ensuring that devices meet safety and performance requirements throughout their lifecycle. 

_____________________________________________

These updates to MHRA serious adverse events reporting aim to enhance safety monitoring and streamline compliance for clinical investigators. By ensuring all serious adverse events are reported promptly and providing easier access to the reporting portal, the MHRA reinforces its commitment to patient safety and regulatory clarity. If you need assistance navigating these changes, feel free to contact us for expert guidance and support.

Learn how MedEnvoy can assist you:

• • • UK Responsible Person
    • UK Regulatory Importer
    • QA Consulting